-
公开(公告)号：EP2623499B1
公开(公告)日：2015-04-22
申请号：EP11829344.8
申请日：2011-09-30
发明人： KUWADA, Takeshi , YOSHINAGA, Mitsukane , ISHIZAKA, Tomoko , WAKASUGI, Daisuke , SHIROKAWA, Shin-ichi , HATTORI, Nobutaka , SHIMAZAKI, Youichi , MIYAKOSHI, Naoki
IPC分类号： C07D249/12 , A61K31/4196 , A61K31/454 , A61K31/4545 , A61K31/46 , A61K31/5377 , A61K31/5386 , A61K31/553 , A61P7/10 , A61P9/12 , A61P17/02 , A61P17/14 , A61P25/00 , A61P25/08 , A61P25/14 , A61P25/16 , A61P25/18 , A61P25/22 , A61P25/28 , A61P25/36 , A61P29/00
CPC分类号： C07D249/12 , C07D401/04 , C07D401/10 , C07D403/10 , C07D405/10 , C07D405/12 , C07D413/10 , C07D413/14 , C07D451/06 , C07D491/08 , C07D491/107 , C07D498/08
-
公开(公告)号：EP2623499A1
公开(公告)日：2013-08-07
申请号：EP11829344.8
申请日：2011-09-30
发明人： KUWADA, Takeshi , YOSHINAGA, Mitsukane , ISHIZAKA, Tomoko , WAKASUGI, Daisuke , SHIROKAWA, Shin-ichi , HATTORI, Nobutaka , SHIMAZAKI, Youichi , MIYAKOSHI, Naoki
IPC分类号： C07D249/12 , A61K31/4196 , A61K31/454 , A61K31/4545 , A61K31/46 , A61K31/5377 , A61K31/5386 , A61K31/553 , A61P7/10 , A61P9/12 , A61P17/02 , A61P17/14 , A61P25/00 , A61P25/08 , A61P25/14 , A61P25/16 , A61P25/18 , A61P25/22 , A61P25/28 , A61P25/36 , A61P29/00
CPC分类号： C07D249/12 , C07D401/04 , C07D401/10 , C07D403/10 , C07D405/10 , C07D405/12 , C07D413/10 , C07D413/14 , C07D451/06 , C07D491/08 , C07D491/107 , C07D498/08
摘要： The present invention provides a 1,2,4-triazolone derivative represented by Formula (1A) having an antagonistic activity on the arginine-vasopressin 1b receptor or a pharmaceutically acceptable salt thereof and provides a pharmaceutical composition comprising the compound or the salt as an active ingredient, in particular, a therapeutic or preventive agent exhibiting favorable pharmacokinetics in a disease such as mood disorder, anxiety disorder, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal disease, drug addiction, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, head injury, inflammation, immune-related disease, or alopecia.
摘要翻译： 本发明提供对精氨酸 - 加压素1b受体具有拮抗活性的式（1A）所示的1,2,4-三唑酮衍生物或其药学上可接受的盐，提供含有该化合物或其盐作为活性成分的药物组合物 成分，特别是在情绪障碍，焦虑症，精神分裂症，阿尔茨海默病，帕金森病，亨廷顿舞蹈症，进食障碍，高血压，胃肠疾病，药物成瘾，癫痫，脑梗塞等疾病中表现出良好的药代动力学的治疗剂或预防剂 ，脑缺血，脑水肿，头部损伤，炎症，免疫相关疾病或脱发。
-
公开(公告)号：EP2772482B1
公开(公告)日：2016-03-09
申请号：EP12843663.1
申请日：2012-10-25
发明人： YOSHINAGA, Mitsukane , KUWADA, Takeshi , MIYAKOSHI, Naoki , ISHIZAKA, Tomoko , WAKASUGI, Daisuke , SHIROKAWA, Shin-ichi , HATTORI, Nobutaka , SHIMAZAKI, Youichi
IPC分类号： C07D207/444 , A61K31/4164 , A61K31/4178 , A61K31/4196 , A61K31/4439 , A61K31/444 , A61K31/454 , A61K31/4545 , A61K31/46 , A61K31/4725 , A61K31/496 , A61K31/537 , A61K31/5377 , A61K31/5386 , A61K31/541 , A61K31/553 , A61P1/04 , A61P9/10 , A61P9/12 , A61P17/14 , A61P25/00
CPC分类号： C07D471/08 , C07D207/444 , C07D231/12 , C07D233/64 , C07D233/70 , C07D233/90 , C07D249/08 , C07D249/10 , C07D249/12 , C07D263/32 , C07D277/20 , C07D277/30 , C07D401/04 , C07D401/10 , C07D403/04 , C07D403/06 , C07D403/10 , C07D413/10 , C07D451/06 , C07D491/107 , C07D498/08
-
公开(公告)号：EP2454240A1
公开(公告)日：2012-05-23
申请号：EP10799955.9
申请日：2010-07-15
发明人： YASUHARA, Akito , SAKAGAMI, Kazunari , OHTA, Hiroshi , HAYASHI, Masato , SHIRASAKI, Yoshihisa , YAMAMOTO, Shuji , SHIMAZAKI, Youichi , ARAKI, Yuko , ABE, Kumi , SUN, Xiang-Min
IPC分类号： C07D233/90 , A61K31/4164 , A61K31/4196 , A61P25/00 , A61P25/04 , A61P25/18 , A61P25/20 , A61P25/22 , A61P25/24 , A61P25/28 , A61P25/30 , A61P43/00 , C07D249/10
CPC分类号： C07D249/10
摘要： The present invention aims to provide novel compounds represented by formula [I] or pharmaceutically acceptable salts thereof: [Formula 1] which are useful for prevention or treatment of diseases such as schizophrenia, Alzheimer's disease, cognitive impairment, dementia, anxiety disorders (e.g., generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, post-traumatic stress disorder, specific phobias, acute stress disorder), depression, drug dependence, convulsion, tremor, pain, or sleep disorders, based on their inhibitory effect against glycine uptake.
摘要翻译： 本发明的目的在于提供可用于预防或治疗精神分裂症，阿尔茨海默氏病，认知障碍，痴呆症，焦虑症（例如，精神分裂症， 广泛性焦虑症，恐慌症，强迫症，社交焦虑症，创伤后应激障碍，特定恐怖症，急性应激障碍），抑郁症，药物依赖性，惊厥，震颤，疼痛或睡眠障碍 抵抗甘氨酸摄取。
-
公开(公告)号：EP2832722A1
公开(公告)日：2015-02-04
申请号：EP13767453.7
申请日：2013-03-29
发明人： YOSHINAGA, Mitsukane , ISHIZAKA, Tomoko , WAKASUGI, Daisuke , SHIROKAWA, Shin-ichi , HATTORI, Nobutaka , KASHIWA, Shuhei , KUWADA, Takeshi , SHIMAZAKI, Youichi
IPC分类号： C07D209/10 , A61K31/405 , A61K31/4184 , A61K31/438 , A61K31/454 , A61K31/4545 , A61K31/5377 , A61K31/5386 , A61K31/55 , A61P1/14 , A61P7/10 , A61P9/10 , A61P9/12 , A61P17/14 , A61P25/00 , A61P25/08 , A61P25/14 , A61P25/16 , A61P25/18 , A61P25/22 , A61P25/28
CPC分类号： C07D491/107 , C07D209/10 , C07D231/56 , C07D235/18 , C07D401/04 , C07D401/12 , C07D403/12 , C07D471/04 , C07D491/08
摘要： The present invention provides agents for treating or preventing diseases such as mood disorder, anxiety disorder, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal disease, drug addiction, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, head injury, inflammation, immune-related disease, alopecia. Specifically, the invention provides fused azole derivatives represented by general formula (I) or pharmaceutically acceptable salts thereof that have an antagonistic action against the arginine-vasopressin 1b receptor:
摘要翻译： 本发明提供用于治疗或预防诸如心境障碍，焦虑症，精神分裂症，阿尔茨海默氏病，帕金森病，亨廷顿舞蹈病，进食障碍，高血压，胃肠疾病，药物成瘾，癫痫，脑梗塞，脑缺血，脑水肿 ，头部损伤，炎症，免疫相关疾病，脱发。 具体而言，本发明提供通式（I）表示的稠合唑衍生物或其可药用盐，其对精氨酸 - 加压素1b受体具有拮抗作用：
-
公开(公告)号：EP2772482A1
公开(公告)日：2014-09-03
申请号：EP12843663.1
申请日：2012-10-25
发明人： YOSHINAGA, Mitsukane , KUWADA, Takeshi , MIYAKOSHI, Naoki , ISHIZAKA, Tomoko , WAKASUGI, Daisuke , SHIROKAWA, Shin-ichi , HATTORI, Nobutaka , SHIMAZAKI, Youichi
IPC分类号： C07D207/444 , A61K31/4164 , A61K31/4178 , A61K31/4196 , A61K31/4439 , A61K31/444 , A61K31/454 , A61K31/4545 , A61K31/46 , A61K31/4725 , A61K31/496 , A61K31/537 , A61K31/5377 , A61K31/5386 , A61K31/541 , A61K31/553 , A61P1/04 , A61P9/10 , A61P9/12 , A61P17/14 , A61P25/00
CPC分类号： C07D471/08 , C07D207/444 , C07D231/12 , C07D233/64 , C07D233/70 , C07D233/90 , C07D249/08 , C07D249/10 , C07D249/12 , C07D263/32 , C07D277/20 , C07D277/30 , C07D401/04 , C07D401/10 , C07D403/04 , C07D403/06 , C07D403/10 , C07D413/10 , C07D451/06 , C07D491/107 , C07D498/08
摘要： The present invention provides agents for treating or preventing diseases such as mood disorder, anxiety disorder, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal disease, drug addiction, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, head injury, inflammation, immune-related disease, alopecia, and so forth.
Specifically, the invention provides azole derivatives represented by general formula (I), or pharmaceutically acceptable salts thereof that have an antagonistic action against the arginine-vasopressin (AVP) V1b receptor:摘要翻译： 本发明提供用于治疗或预防诸如心境障碍，焦虑症，精神分裂症，阿尔茨海默氏病，帕金森病，亨廷顿舞蹈病，进食障碍，高血压，胃肠疾病，药物成瘾，癫痫，脑梗塞，脑缺血，脑水肿 ，头部损伤，炎症，免疫相关疾病，脱发等。 具体而言，本发明提供了具有对抗精氨酸 - 加压素（AVP）V1b受体的拮抗作用的由通式（I）表示的唑衍生物或其药学上可接受的盐：
-
公开(公告)号：EP2409976A1
公开(公告)日：2012-01-25
申请号：EP10753606.2
申请日：2010-03-19
发明人： YASUHARA, Akito , YAMAMOTO, Shuji , OHTA, Hiroshi , SHIRASAKI, Yoshihisa , SAKAGAMI, Kazunari , HAYASHI, Masato , SHIBATA, Tsuyoshi , SHIMAZAKI, Youichi , ARAKI, Yuko , ABE, Kumi , SUN, Xiang-Min
IPC分类号： C07D405/12 , A61K31/4178 , A61K31/4196 , A61K31/437 , A61K31/4439 , A61P25/08 , A61P25/14 , A61P25/18 , A61P25/20 , A61P25/22 , A61P25/24 , A61P25/28 , A61P25/30 , A61P43/00 , C07D405/14 , C07D409/12 , C07D471/04
CPC分类号： C07D471/04 , C07D405/12 , C07D405/14 , C07D409/12
摘要： The present invention aims to provide novel compounds of formula [I] or pharmaceutically acceptable salts thereof that are based on a glycine uptake inhibiting action and which are useful in the prevention or treatment of such diseases as schizophrenia, Alzheimer's disease, cognitive dysfunction, dementia, anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsory disorder, social anxiety disorder, posttraumatic stress disorder, specific phobia, acute stress disorder, etc.), depression, drug addiction, spasm, tremor, and sleep disorder:
摘要翻译： 本发明旨在提供基于甘氨酸摄取抑制作用并可用于预防或治疗诸如精神分裂症，阿尔茨海默氏病，认知功能障碍，痴呆等的疾病的新型式[I]化合物或其药学上可接受的盐。 焦虑症（广泛性焦虑症，恐慌症，强迫症，社交焦虑症，创伤后应激障碍，特定恐惧症，急性应激障碍等），抑郁症，药物成瘾，痉挛，震颤和睡眠障碍：
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.021 秒)
